Paul Williams: Yeah. I think, initially, we wanted to make sure that all of our partners were adequately stocked to meet demand, and I think as the demand continues to grow, we will replenish that demand relative to what those individual retailers and e-commerce sites need in terms of what they want to keep in terms of on hand and what the run rate continues to move and progress at.
Nick Lorusso: Great. Thanks very much.
Operator: Thank you. And our next question coming from the line of Frank DiLorenzo with Singular Research.
Frank DiLorenzo: Good afternoon. Thanks for taking my call. I had a couple of questions around the updated guidance. One was related to the Anthrax business and the lower guidance. The difference in the previous guidance in current, will some of that be made up into 2024, is that a timing issue on procurement, et cetera? And then separate from that, could you give us a little more granularity on the adjusted gross margin guidance on what’s pressuring that there and would that subside into 2024? Thank you.
Haywood Miller: Yeah. Frank, thanks for the question. As far as the Anthrax guidance is concerned, as we mentioned, the guidance at the high end contemplates the receipt of the next order for 2023 procurement. As we indicated, we are all aligned towards having that be received and in time for deliveries by the end of the year. But just given the current situation in Congress with the continuing resolution, there’s some uncertainty about whether or not that could slip out of this year and into next year. So that’s the way to think about that. As far as the adjusted gross margin, that’s really just a mix element in terms of the overall product mix reflected by the revised guidance and some other one-time costs that have come into play throughout the course of the year.
Frank DiLorenzo: Thanks. And one other question this time on the NARCAN business, can you talk about maybe some non-traditional markets, if you are seeing any movement there, there’s potential for some penetration into areas such as maybe more industrial corporate penetration first aid kits, things like that? Thank you.
Haywood Miller: Paul, do you want to take that one?
Paul Williams: Yeah. Happy too. Right. So while our initial launch was primarily geared towards the retail pharmacy and e-commerce sites. Obviously, as we call it the business-to-business segment is obviously a key area for us. And we are looking to, I think, launch into that segment fully in the beginning of the year, but we are in active conversations with multiple stakeholders across the B2B segment as we are defining it.
Frank DiLorenzo: Okay. Thank you.
Operator: Thank you, and thank you, all. And with that, ladies and gentlemen, we now conclude the call. Thank you for your participation. Please note an archived version of today’s webcast, as well as a PDF version of the slides used during today’s call will be available later today and accessible through the Investors landing page on the company website. Thank you, again. We look forward to speaking with you all in the future. Good-bye.
